What Is Hindsight Bias In Investing?
You’ve probably heard the expression “hindsight is 20/20.” That saying…
Buy
60
WGS Quote, Financials, Valuation and Earnings
Last price:
$95.07
Seasonality move
:
20.96%
Day range:
$99.58 - $105.00
52-week range:
$8.10 - $115.60
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
9.19x
P/B ratio:
11.95x
Volume:
705.4K
Avg. volume:
1.1M
1-year change:
1086.2%
Market cap:
$2.9B
Revenue:
$305.5M
EPS (TTM):
-$1.96
Analysts' Opinion
-
Consensus RatingGeneDx Holdings has received a consensus rating of Leans Bullish. The company's average rating is a Leans Bullish based on 3 Buy ratings, 3 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $107.33, GeneDx Holdings has an estimated upside of 2.82% from its current price of $100.59.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $80.00 representing 100% downside risk from its current price of $100.59.
Fair Value
-
According to the consensus of 6 analysts, GeneDx Holdings has 2.82% upside to fair value with a price target of $107.33 per share.
WGS vs. S&P 500
-
Over the past 5 trading days, GeneDx Holdings has overperformed the S&P 500 by 5.48% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
GeneDx Holdings does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
GeneDx Holdings has grown year-over-year revenues for 4 quarters straight. In the most recent quarter GeneDx Holdings reported revenues of $95.6M.
Earnings Growth
-
GeneDx Holdings has grown year-over-year earnings for 0 quarters straight. In the most recent quarter GeneDx Holdings reported earnings per share of $0.23.
Enterprise value:
2.8B
EV / Invested capital:
9.56x
Price / LTM sales:
9.19x
EV / EBIT:
--
EV / Revenue:
9.30x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-83.58x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$194.4M
Return On Assets:
-12.88%
Net Income Margin (TTM):
-17.12%
Return On Equity:
-24.23%
Return On Invested Capital:
-19.51%
Operating Margin:
9.21%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | $234.7M | $202.6M | $305.5M | $57.4M | $95.6M | |
| Gross Profit | -$26.8M | $90M | $194.4M | $30.8M | $66.2M | |
| Operating Income | -$457.5M | -$170.2M | -$23.2M | -$25.6M | $8.8M | |
| EBITDA | -$356.4M | -$139.3M | -$25.2M | -$19.5M | $14.4M | |
| Diluted EPS | -$54.45 | -$7.44 | -$1.96 | -$0.92 | $0.23 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $174.1M | $483.5M | $212.6M | $182.3M | $198M | |
| Total Assets | $251.6M | $554.1M | $490.9M | $418.8M | $419.4M | |
| Current Liabilities | $73.4M | $101.3M | $144.3M | $58.8M | $54.8M | |
| Total Liabilities | $581.7M | $166M | $237.2M | $190.7M | $174.1M | |
| Total Equity | -$330.1M | $388.1M | $253.7M | $228M | $245.2M | |
| Total Debt | $20.7M | $11M | $11M | $52.7M | $51.9M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$319.2M | -$180.1M | -$28.5M | -$29.9M | -$3.2M | |
| Cash From Investing | -$141.3M | -$43.7M | -$30.1M | -$4.9M | -$519K | |
| Cash From Financing | $197.3M | $186.2M | $44.2M | $47.1M | $31M | |
| Free Cash Flow | -$333.5M | -$185.9M | -$34M | -$32.2M | -$6.2M | |
WGS
Sector
Market Cap
$2.9B
$39.2M
Price % of 52-Week High
90.3%
45.99%
Dividend Yield
0%
0%
Shareholder Yield
-2.58%
-0.81%
1-Year Price Total Return
1037.15%
-38.63%
Beta (5-Year)
--
0.774
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$98.26
200-day SMA
Buy
Level
$58.65
Bollinger Bands (100)
Buy
Level
69.49 - 93.09
Chaikin Money Flow
Sell
Level
-67.8M
20-day SMA
Buy
Level
$97.37
Relative Strength Index (RSI14)
Buy
Level
55.50
ADX Line
Buy
Level
15.77
Williams %R
Sell
Level
-6.5796
50-day SMA
Buy
Level
$86.07
MACD (12, 26)
Buy
Level
3.71
25-day Aroon Oscillator
Buy
Level
8
On Balance Volume
Neutral
Level
2M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (3.86)
Buy
CA Score
(Annual)
Level (-0.1319)
Buy
Beneish M-Score
(Annual)
Level (-2.5737)
Buy
Momentum Score
Level (10)
Sell
Ohlson Score
Level (1.8894)
Buy
Piotroski F Score
(Annual)
Level (6)
Buy
Quality Ratio Score
Level (6)
Sell
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
GeneDx Holdings Corp delivers personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. The company is at the forefront of transforming healthcare through its various exome and genome testing and interpretation, fueled by one of the world’s substantial rare disease data sets.
Stock Forecast FAQ
In the current month, WGS has received 3 Buy ratings 3 Hold ratings, and 0 Sell ratings. The WGS average analyst price target in the past 3 months is $107.33.
-
Where Will GeneDx Holdings Stock Be In 1 Year?
According to analysts, the consensus estimate is that GeneDx Holdings share price will rise to $107.33 per share over the next 12 months.
-
What Do Analysts Say About GeneDx Holdings?
Analysts are divided on their view about GeneDx Holdings share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that GeneDx Holdings is a Sell and believe this share price will drop from its current level to $80.00.
-
What Is GeneDx Holdings's Price Target?
The price target for GeneDx Holdings over the next 1-year time period is forecast to be $107.33 according to 6 Wall Street analysts, 3 of them rate the stock a Buy, 0 rate the stock a Sell, and 3 analysts rate the stock a Hold.
-
Is WGS A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for GeneDx Holdings is a Leans Bullish. 3 of 6 analysts rate the stock a Leans Bullish at this time.
-
How Can I Buy Shares Of WGS?
You can purchase shares of GeneDx Holdings via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase GeneDx Holdings shares.
-
What Is The GeneDx Holdings Share Price Today?
GeneDx Holdings was last trading at $95.07 per share. This represents the most recent stock quote for GeneDx Holdings. Yesterday, GeneDx Holdings closed at $100.59 per share.
-
How To Buy GeneDx Holdings Stock Online?
In order to purchase GeneDx Holdings stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Rivian a Good Stock a Buy?
Rivian Automotive (RIVN) had an initial IPO of close to…
Will Chevron Acquire Hess?
Long-time Buffett favorite in the energy sector Chevron (NYSE:CVX) is…
Stock Ideas
Buy
58
Is AAPL Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 37x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 41x
Buy
53
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Alerts
Sell
29
UNF alert for Mar 26
UniFirst [UNF] is down 0.02% over the past day.
Sell
30
KEQU alert for Mar 26
Kewaunee Scientific [KEQU] is down 3.5% over the past day.
Buy
82
EPAC alert for Mar 26
Enerpac Tool Group [EPAC] is down 0.45% over the past day.
